A Randomized Study Evaluating Oral Fusidic Acid (CEM-102) in Combination With Oral Rifampin Compared With Standard-of-Care Antibiotics for Treatment of Prosthetic Joint Infections: A Newly Identified Drug–Drug Interaction | Zendy

Richard Pushkin | Zendy; Maria D. Iglesias-Ussel | Zendy; Kara Keedy | Zendy; Chris MacLauchlin | Zendy; Diane R. Mould | Zendy; Richard Berkowitz | Zendy; Stephan Kreuzer | Zendy; Rabih O. Darouiche | Zendy; David Oldach | Zendy; Prabha Fernandes | Zendy

Open Access

A Randomized Study Evaluating Oral Fusidic Acid (CEM-102) in Combination With Oral Rifampin Compared With Standard-of-Care Antibiotics for Treatment of Prosthetic Joint Infections: A Newly Identified Drug–Drug Interaction

Author(s) -

Richard Pushkin,

Maria D. Iglesias-Ussel,

Kara Keedy,

Chris MacLauchlin,

Diane R. Mould,

Richard Berkowitz,

Stephan Kreuzer,

Rabih O. Darouiche,

David Oldach,

Prabha Fernandes

Publication year - 2016

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciw665

Subject(s) - medicine , fusidic acid , antibiotics , pharmacokinetics , randomized controlled trial , drug , drug interaction , rifamycin , surgery , pharmacology , staphylococcus aureus , biology , bacteria , microbiology and biotechnology , genetics

Fusidic acid (FA) has been used for decades for bone infection, including prosthetic joint infection (PJI), often in combination with rifampin (RIF). An FA/RIF pharmacokinetic interaction has not previously been described.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research